Overview Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia Status: Not yet recruiting Trial end date: 2028-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN). Phase: Phase 2 Details Lead Sponsor: University of MiamiCollaborator: GlaxoSmithKline